New Zealand GLP-1 in May 2026: Mounjaro launch matures, Wegovy still pending, Foundayo Medsafe outlook

The New Zealand GLP-1 picture is younger and tighter than its Australian neighbour. Eli Lilly launched Mounjaro in NZ in February 2026 via Medsafe approval; private telehealth operators (Well Revolution as the dominant player, Pocket Lab as the accredited alternative) started stocking from launch week. Novo Nordisk's Wegovy remains pending Medsafe filing as of May 2026. Foundayo (orforglipron, FDA-approved April 1) sits 12-18 months behind on the Medsafe trajectory.

This is the May 2026 NZ snapshot. Companion to the UK May update and Australia buyer's guide · same regulatory through-line, different national specifics.

What's available today

Mounjaro (tirzepatide) is the headline · Medsafe approval February 2026, Lilly direct supply via NZ-licensed pharmacies, and the two main private telehealth operators have stocked it from launch:

• Well Revolution (scorecard) is the dominant NZ operator. Explicit Mounjaro + brand-semaglutide menu, prescribing via NZ-registered clinicians. Routable per the Panya rubric.
• Pocket Lab (scorecard) is the smaller accredited alternative. Same Medsafe-channel supply, more limited geographic coverage.

Both operators source brand pharmacy via the standard NZ supply chain · no compounded GLP-1 market in NZ at any meaningful scale (Medsafe enforcement on unapproved supply has been firm).

Wegovy (semaglutide injectable) is still pending Medsafe filing as of May 2026. Novo Nordisk has indicated NZ market entry plans without committing to a public timeline. NZ readers wanting injectable semaglutide today are routing through Australia or Singapore · not legal supply paths and Panya does not recommend them.

Ozempic (semaglutide for type 2 diabetes) is Medsafe-approved with PHARMAC funding restrictions limiting subsidy to specific T2D criteria. Off-label weight-management prescribing is uncommon vs the AU pattern; most NZ private telehealth operators steer toward Mounjaro for the off-label-weight-loss case rather than Ozempic.

Saxenda (liraglutide) has been Medsafe-approved for years and remains available · pricing is higher per-month-equivalent than tirzepatide and efficacy is materially lower (~5-7% weight loss vs ~22%). Routable as a fallback if tirzepatide isn't accessible, not as a primary recommendation.

What's coming

Foundayo (orforglipron): Lilly's oral small-molecule GLP-1, FDA-approved April 1, 2026. The Medsafe pathway typically runs 12-18 months behind the FDA for a new molecular entity, so realistic NZ availability is mid 2027 to early 2028. Lilly's direct-distribution playbook in the US (Ro partnership at $149/mo cash) is a template for what the NZ private market will likely look like once Foundayo lands.

Wegovy injectable: Novo Nordisk submission to Medsafe is the gating question. If filed in 2026, decision likely H1 2027.

Oral Wegovy 25mg: launched in the US December 2025, available in private UK pharmacies January 2026. NZ availability follows Wegovy injectable approval at minimum, so 2027+.

Routing in May 2026 (three reader profiles)

Profile 1 · BMI 30+ wanting maximum efficacy, willing to pay privately

Well Revolution NZ. Mounjaro at the NZ private price (~NZ$300-450/mo depending on dose), direct-supply via Medsafe channel, NZ-registered clinicians. The cleanest answer in May 2026.

Profile 2 · Tighter budget, willing to accept lower efficacy

Saxenda is the routable fallback. Lower upfront cost, lower efficacy (5-7% weight loss vs 22% for tirzepatide). Available via Well Revolution and direct from major NZ pharmacies with Rx. Not a Panya routing recommendation as a primary answer · just a real fallback for the cohort that can't reach Mounjaro pricing.

Profile 3 · Wanting an oral path

Wait. The needle-free options (oral Wegovy 25mg, Foundayo) are not yet Medsafe-approved. Realistic earliest Foundayo NZ availability is mid 2027 to early 2028. If you specifically need oral and can't wait, your routes are international travel (Singapore + Australia have oral options legally) · which has its own logistics, and isn't a Panya recommendation.

What we're watching

• PHARMAC funding decisions on Mounjaro for weight management. Currently no PHARMAC subsidy for off-label weight-management prescribing; private cash-pay is the only path. PHARMAC's process is conservative; expansion would be 2027+ if it happens at all.
• Wegovy injectable Medsafe filing announcement. Whenever Novo confirms.
• Foundayo Medsafe submission timeline. Usually announced when the EMA submission is public.
• Telehealth competitive entry. NZ market is currently a Well Revolution / Pocket Lab effective duopoly. Australian operators (Juniper, Pilot) have not yet announced NZ expansion despite the cross-Tasman regulatory similarity.

For the May 2026 cross-region snapshot: /blog/peptide-pulse-may-2026. For the methodology: /blog/11-signals-vendor-rubric. For the AU + UK parallels: /blog/australia-glp1-buyers-guide-may-2026, /blog/uk-glp1-may-2026-nhs-update.